Literature DB >> 27907882

Thorium-229 quantified in historical Thorium-228 capsules.

Sven Boden1, Koen Vints1, Simone Cagno2, Dominic Maertens1, Karen Van Hecke1, Thomas Cardinaels3.   

Abstract

Thorium-229 is a valuable, but scarce, radionuclide for nuclear clock applications or targeted alpha therapy. While it is mostly produced by the decay of 233U, 229Th can also be produced by neutron irradiation of 226Ra. At SCK•CEN, capsules containing mainly 228Th (by-product of 226Ra irradiation) were characterized to quantify the present amounts of 229Th, 228Th, 227Ac, 226Ra with high resolution gamma spectroscopy, after a decay period of 40 years in which 228Th has decayed. High purity 229Th was quantified, and after recovery using radiochemical separation processes, it can be used to support ongoing research.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  (213)Bi; (225)Ac; (226)Ra; (227)Ac; (228)Th; (229)Th; In-situ gamma-ray spectroscopy; Nuclear clock; Targeted alpha therapy

Year:  2016        PMID: 27907882     DOI: 10.1016/j.apradiso.2016.11.012

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  2 in total

1.  Gamma counting protocols for the accurate quantification of 225Ac and 213Bi without the need for a secular equilibrium between parent and gamma-emitting daughter.

Authors:  Dayana Castillo Seoane; Marijke De Saint-Hubert; Stephen Ahenkorah; Clarita Saldarriaga Vargas; Maarten Ooms; Lara Struelens; Michel Koole
Journal:  EJNMMI Radiopharm Chem       Date:  2022-10-23

Review 2.  Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside.

Authors:  Stephen Ahenkorah; Irwin Cassells; Christophe M Deroose; Thomas Cardinaels; Andrew R Burgoyne; Guy Bormans; Maarten Ooms; Frederik Cleeren
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.